Preclinical studies carried out on metastatic prostate cancer cells showed that the c-src inhibitors Bosutinib and Saracatinib affect tumor cell proliferation and reduce cancer-induced osteolysis by inhibiting the phosphorylation of AKT, MAPK and FAK [108,109]. This evidence concerns the gene SRC and cancer.